



## Bioisosteric modification of known fucosidase inhibitors to discover a novel inhibitor of $\alpha$ -L-fucosidase†

Chandramohan Bathula,<sup>‡,a</sup> Shreemoyee Ghosh,<sup>‡,b</sup> Santanu Hati,<sup>a</sup> Sayantan Tripathy,<sup>c</sup> Shailja Singh,<sup>c</sup> Saikat Chakrabarti<sup>b</sup> and Subhabrata Sen<sup>\*a</sup>

Bioisosteric modification of known fucosidase inhibitors **A** and **B**, resulted in three new types of molecules, **4b**, **5c** and **6a** (belonging to fuopyridinedione, thiohydantoin and hydantoin chemotypes) that could potentially bind to  $\alpha$ -L-fucosidase (bovine kidney origin). Molecular docking revealed and compared the putative binding interaction between **4b**, **5c** and **6a** with **A** and **B** against the active site of a homology model of  $\alpha$ -L-fucosidase. Based on this initial investigation, design and synthesis of a library of small molecules based on fuopyridinedione, thiohydantoin and hydantoin, followed by their *in vitro* screening against  $\alpha$ -L-fucosidase (bovine kidney origin) generated a potent inhibitor (compound **4e**) with  $IC_{50}$  of  $\sim 0.7$   $\mu$ M. Compound **4e** possessed no cytotoxic properties when tested against healthy mammalian COS-1 cells. Reaction kinetics study suggested it to be a mixed inhibitor. Finally compounds **4a**, **b**, **e** and **f**, bearing the fuopyridinedione motif also exhibited substantial inhibition of the proliferation of MCF 7 breast cancer cells.

Received 9th October 2016  
Accepted 21st November 2016

DOI: 10.1039/c6ra24939f  
[www.rsc.org/advances](http://www.rsc.org/advances)

## Introduction

$\alpha$ -Glycosidases, belonging to a family of glycoside hydrolases, are enzymes that help in the hydrolysis of glycosidic bonds in complex sugars.<sup>1</sup>  $\alpha$ -L-Fucosidases are glycosidases that are involved in the hydrolysis of the  $\alpha$ -1,6-linked fucose joined to the reducing end of *N*-acetylglucosamine moiety of the glycoproteins.<sup>2</sup> Along with glycosyltransferases they form the major catalytic component for the making and breaking of glycosidic bonds.<sup>3</sup>  $\alpha$ -L-Fucosidases play an important role in the cleaning of the nature by degrading cellulose and hemicellulose.<sup>4</sup> They are also involved in normal functioning of cells along with their roles in antibacterial defense mechanisms, and viral pathogenesis.<sup>5</sup> Recent reports indicated that the activity of human  $\alpha$ -L-fucosidase 2 is critical for the pathogenesis of *Helicobacter pylori* which in turn has implications in gastric cancer among other diseases.<sup>6</sup>  $\alpha$ -L-Fucosidase deficiency leads to various metabolic disorders, tumor occurrences and metastasis.<sup>7</sup> Inhibition of  $\alpha$ -L-fucosidases could lead to the synthesis of disorganized

oligosaccharides that in turn could disrupt cell-cell and cell-virus recognition process.<sup>8–10</sup> For these reasons,  $\alpha$ -L-fucosidases are clinically important targets and the design and synthesis of potent and selective inhibitors remains an attractive goal.<sup>10</sup>

Bioisosteric modification is a replacement strategy for rational design of new drugs that involves substitution of functional groups of a bioactive molecule with chemical moieties that possess similar physical or chemical attributes to generate better biological responses, be it potency, adsorption, dissolution, improvement of selectivity, metabolic stability, reduction of side effects and *etc.* For example, in drug discovery fluorine is one of the most common bioisostere of hydrogen.<sup>11</sup> Other than providing metabolic stability it also influences lipophilicity of the resulting molecule. Carboxylic acid bioisosteres such as oxadiazoles, oxazole, tetrazoles and *etc.* provide enhancement of potency and increase of lipophilicity.<sup>12</sup> Similarly, bioisosteric transformation of amide with trifluoroethylamine in cathepsin K inhibitors generated analogs with improved potency, selectivity and metabolic stability.<sup>13</sup>

Herein we report discovery of a novel inhibitor of  $\alpha$ -L-fucosidase (bovine kidney origin), based on arylidenefuopyridinedione scaffold *via* bioisosteric modification of known fucosidase inhibitors **A** and **B** (Fig. 1).<sup>10d,e</sup> The initial design resulted in three diverse molecules (**4b**, **5c** and **6a**) belonging to different chemotypes such as hydantoin, thiohydantoin and fuopyridinedione. The choice of the compounds was rationalized by their molecular docking against a homology model of  $\alpha$ -L-fucosidase and comparing the binding interactions with the ones for **A** and **B**. A library was synthesized based on the

<sup>a</sup>Department of Chemistry, School of Natural Sciences, Shiv Nadar University, Tehsil Dadri, Chhethra, Uttar Pradesh 201314, India. E-mail: subhabrata.sen@snu.edu.in

<sup>b</sup>Structural Biology and Bio-Informatics Division, CSIR-Indian Institute of Chemical Biology, 4, Raja SC Mullick Road, Kolkata, West Bengal 700032, India

<sup>c</sup>Department of Life Sciences, School of Natural Sciences, Shiv Nadar University, Tehsil Dadri, Chhethra, Uttar Pradesh 201314, India

† Electronic supplementary information (ESI) available. See DOI: 10.1039/c6ra24939f

‡ Equal contributors.






Fig. 1 The scheme depicts representative  $\alpha$ -L-fucosidase inhibitors (A and B) that inspired the design of compound 4b, 5c and 6a.

designed scaffolds and enzymatic profiling of the library revealed that one of the compounds, **4e**, inhibits  $\alpha$ -L-fucosidase (bovine kidney origin) substantially. Mechanistic study revealed that the molecule binds to the enzyme as a mixed inhibitor. Its molecular docking with  $\alpha$ -L-fucosidase indicated potential binding pockets of the enzyme. Further screening of the furo-pyridinedione analogs **4a-f** against MCF 7 breast cancer cells indicated promising antiproliferative activity.

## Results and discussion

### Design

To begin with the design of compounds, we screened the literatures for the available  $\alpha$ -L-fucosidase inhibitors. In our search for small molecule heterocycles as suitable inhibitors of  $\alpha$ -L-fucosidase we selected **A** and **B** that exhibited inhibitory activity in sub  $\mu$ mol range against bovine  $\alpha$ -L-fucosidase (Fig. 1).<sup>10d,e</sup> We intended to design novel molecules inspired from the heterocyclic as well as the sugar component of these compounds. Hence to mimic the multihydroxylated cyclopentenyl benzylamine **A** an intuitive transformation to the thiohydantoin and hydantoin provided compounds **5c** and **6a**. We felt it will be interesting to replace the chiral hydroxylated functionalities of **A** at C<sub>2</sub> and C<sub>4</sub> with dicarbonyl and thiocarbonyl functionalities. The C<sub>2</sub> and C<sub>4</sub> in the ring system were replaced with the corresponding nitrogen bioisosteres. In a similar manner the phthalimide inhibitor **B**, that inhibited bovine- $\alpha$ -L-fucosidase with an IC<sub>50</sub> of 0.21  $\mu$ M, was intuitively replaced with furo-pyridinedione compound **4b**. The N-functionality of the phthalimide was substituted with its corresponding bioisostere oxygen and one of the amide carbonyls was replaced with an arylidene

functionality. The arylidene functionalities were introduced with the hope of better binding over the original molecules **A** and **B** against the bovine  $\alpha$ -L-fucosidase (Fig. 1).

### Molecular docking and analysis of relevant 2D descriptors

To rationalize our design, compounds **A** and **B** along with **4b**, **5c** and **6a** were docked against a homology model created from *Bos taurus*  $\alpha$ -L-fucosidase considering catalytic N-terminal region of *Thermotoga maritima*  $\alpha$ -L-fucosidase (PDB ID: 2ZXD) as the template. FlexX program was used for docking.<sup>14</sup>

Fig. 2A shows the best docking pose of compound **A** with the homology model. It shows a hydrogen bonding between C<sub>3</sub> hydroxy group of **A** and Q245 residue along with a couple of hydrophobic interactions with W248 (Fig. 2B). A  $\pi$ -stacking was also observed between the N-benzyl functional group of **A** and W20 residue. Interestingly compound **B** binds to the homology model via two hydrogen bonding interactions with H24 and L226 residues, two hydrophobic interactions between the imide ring of **B** with W20 and Y33 residues at the active site of the model. Finally a cation–pi interaction with residues H24 and  $\pi$ -stacking with W20 was also observed.

Fig. 3A depicts the docking of **4b**, **5c** and **6a** with *Bos taurus*  $\alpha$ -L-fucosidase. The best FlexX docking pose indicated probable hydrogen bonds between the azobenzofuran ring of compound **4b** (green) and K226, K224, R208, D174, Y126 and H83 residues of *Bos taurus*  $\alpha$ -L-fucosidase. A likely pi–pi stacking interaction between benzothiophene ring and W20 is also shown. Fig. 3B provides the best pose of docking of compound **5c** to *Bos taurus*  $\alpha$ -L-fucosidase. The 2-thiohydantoin ring of compound **5c** (purple) forms 10 hydrogen bonds with K226, W20, H83, Y126,




Fig. 2 2-Dimensional view of the representative poses of **A** and **B** with respect to the homology model of *Bos taurus*  $\alpha$ -L-fucosidase. Probable interacting residues within the 5 Å of the docked compounds are marked.

D174 and R208 in the active site. Finally Fig. 3C shows the best FlexX derived pose of docking of compound **6a** to *Bos taurus*  $\alpha$ -L-fucosidase. The hydantoin moiety of compound **6a** (grey) forms 3 hydrogen bonds with K141 and H83 in the active site. Nitrobenzene ring forms a possible hydrophobic pi-stacking interaction with W20. Nitro group of the nitrobenzene ring forms 4 hydrogen bonds with Y126, H7 and K224.

A closer look at the docking structure of **A** with the homology model of *Bos taurus*  $\alpha$ -L-fucosidase indicated multiple interactions of phenyl substitution of the exocyclic amine with several amino acid residues on the enzyme (Fig. 2A). The hydrogen bonding with exocyclic hydroxyl group further strengthens the interaction. Similar interaction was evoked by the arylidene moiety of **5c** and **6a** (which were inspired from **A**) as they mimicked the benzylidene moiety of **A**. Additionally when the cyclopentane ring got replaced with hydantoin and thiohydantoin moieties, the nitrogen functionalities present in the new ring systems enhanced the binding interactions (Fig. 3A). In case of **B**, the phthalimide functionality generated substantial binding interactions as depicted in Fig. 2B. Hence we felt it was pragmatic to modify it bioisostERICALLY to the novel pyridofuranone moiety containing the arylidene functionality (**4b**) that could enhance the interactions further. This was supported from the above docking experiments.

For the better understanding of the suitability of the new scaffolds **4b**, **5c** and **6a** over **A** and **B**, we have quantified the binding strength of the molecules against *Bos taurus*  $\alpha$ -L-fucosidase as depicted in Table 1. As the value suggests compounds, **4b** and **6a** exhibited much stronger binding against the enzyme compared to **A** and **B** (Table 1).

The 2D structures of the compounds were built and various 3D conformation was searched using conformational search tool. The conformation having least energy was selected for docking studies. For docking studies both the modelled structure and template structure (PDB ID: 2ZX5) were aligned and the complex ligand in the crystal structure (PDB ID: 2ZX5) were used as the binding site. Protein preparation was performed using FlexX prepare receptor wizard and finally the docking was done using FlexX program with default parameters.

Next, in a bid to understand the physicochemical indications rudimentary to the design we computed few relevant medicinal chemistry descriptors of **4b**, **5c** and **6a** along with **A** and **B** (Table 2).

From the information above it was revealed that all the compounds adhere to the Lipinsky's rules (Table 1). The TPSA of all the compounds are  $<140$  Å<sup>2</sup> thereby indicating good permeability of cell membranes. Interestingly the designed compounds **4b**, **5c** and **6a** has log *P* in the range of 1.1–3.6




Fig. 3 Structural views of the representative poses of candidate compounds with respect to *Bos taurus*  $\alpha$ -L-fucosidase. Three-dimensional views of representative docking poses of compounds **4b**, **5c** and **6a** (panel A, B, and C, respectively) derived from FlexX program are shown in cartoon modes. Probable interacting residues within the 5 Å of the docked compounds are marked in orange. Images were generated using the CHIMERA software.<sup>15</sup>



Table 1 FlexX docking scores of compounds with respect to *Bos taurus*  $\alpha$ -L-fucosidase

| Compound #   | Compound 4b | Compound 5c | Compound 6a | Compound A | Compound B |
|--|-------------|-------------|-------------|------------|------------|
| <i>Bos taurus</i> $\alpha$ -L-fucosidase-docking score | -18.9486    | -9.4218     | -22.1022    | -14.6481   | -10.2268   |

Table 2 Predicted physicochemical properties of A, B and 4b, 5c and 6a

| Compounds | log P | Mol. wt | HBD | HBA | TPSA  | No. of rotatable bonds | Solubility ( $\log S_w$ ) [mol L <sup>-1</sup> ] | Lipinski drug like |
|-----------|-------|---------|-----|-----|-------|------------------------|--|--------------------|
| <b>A</b>  | 0.54  | 237.30  | 4   | 4   | 72.72 | 3                      | -1.07014   | 1                  |
| <b>B</b>  | 0.18  | 276.29  | 3   | 5   | 89.87 | 1                      | -1.7297  | 1                  |
| <b>4b</b> | 3.61  | 309.35  | 2   | 3   | 55.4  | 1                      | -5.7326  | 1                  |
| <b>5c</b> | 1.869 | 289.18  | 2   | 2   | 73.22 | 1                      | -4.6118  | 1                  |
| <b>6a</b> | 1.17  | 233.18  | 2   | 2   | 104.0 | 2                      | -3.2700  | 1                  |

(Table 2) which indicated better membrane absorption and binding ability to the enzyme and poor aqueous solubility when compared with **A** and **B**. Low  $\log S_w$  of compounds of **4b**, **5c** and **6a** indicated that substituting the aryl or heteroaryl appendages to the central motif of these compounds with polar functionalities may improve the overall solubility (Table 2).

The analyses and comparison of the binding results and the physicochemical properties of **A/B** and **4b**, **5c** and **6a** encouraged us to synthesize the library of compounds with hydantoin, thiohydantoin and furopyridinedione motifs and subsequently screen them against bovine- $\alpha$ -L-fucosidase.

## Chemistry

With the molecular design rationalized through docking experiments, we decided to obtain a library based on **4b**, **5c** and **6a**. We envisioned Knoevenagel condensation reaction between

the central motifs *i.e.* hydantoin, thiohydantoin and furopyridinedione with appropriate aldehydes, as a suitable strategy to afford the desired compounds. Accordingly diverse bases *viz.* morpholine, piperidine, triethyl amine, diisopropyl ethylamine and pyrrolidine in variety of solvents such a methanol, ethanol, isopropanol, dimethyl formamide and acetonitrile were screened in the reaction of hydantoin, thiohydantoin and furopyridinedione with 3,5-difluorobenzaldehyde. Ethanol with piperidine provided the best condition for the Knoevenagel reaction yielding **4c**, **5b** and **6c** in 75–92% yield. Incidentally the final product precipitated from the reaction mixture and could be purified by multiple diethyl ether wash. Hence, this facile optimized protocol enabled us to generate the library of molecules (**4**, **5** and **6a–f**) through combinatorial synthesis.

Accordingly, the Knoevenagel reaction was conducted in parallel in custom made reaction chambers with pre-tared vials with ethanol (EtOH) solution of furopyridinedione (0.24 M),


Scheme 1 Combinatorial synthesis of the library of compounds **4a-f**, **5a-f** and **6a-f**.

Table 3 *In vitro* screening of 4a–f, 5a–f and 6a–f against  $\alpha$ -L-fucosidase

| Entry | Compound # | Compounds | IC <sub>50</sub> against $\alpha$ -fucosidase <sup>a</sup><br>(bovine kidney) in $\mu$ M |
|-------|------------|-----------|--|
| 1     | 4a         |           | 24.9   |
| 2     | 4b         |           | 21.3   |
| 3     | 4c         |           | >100   |
| 4     | 4d         |           | 1.8  |
| 5     | 4e         |           | 0.68   |
| 6     | 4f         |           | 2.9  |
| 7     | 5a         |           | 18.7   |
| 8     | 5b         |           | 43.6   |
| 9     | 5c         |           | 24.1   |
| 10    | 5d         |           | 28.3   |
| 11    | 5e         |           | 24.2   |
| 12    | 5f         |           | 31.2   |



Table 3 (Contd.)

| Entry           | Compound #  | Compounds | IC <sub>50</sub> against $\alpha$ -fucosidase <sup>a</sup><br>(bovine kidney) in $\mu$ M |
|-----------------|-------------|-----------|--|
| 13              | <b>6a</b>   |           | 6.4  |
| 14              | <b>6b</b>   |           | 48.2   |
| 15              | <b>6c</b>   |           | 50.8   |
| 16              | <b>6d</b>   |           | >100   |
| 17              | <b>6e</b>   |           | >100   |
| 18              | <b>6f</b>   |           | 19.1   |
| 19 <sup>b</sup> | Swainsonine |           | 27.5   |

<sup>a</sup> Concentration of compound that reduced enzyme activity by 50%. <sup>b</sup> The concentration was observed in our laboratory assay method.

thiohydantoin (0.34 M) and hydantoin (0.4 M) at 80 °C (Scheme 1). On completion of the reaction final products precipitated and the supernatant ethanol was removed. The precipitate was subsequently washed (twice) with diethyl ether. The whole operation was conducted in parallel using Tecan Evo Freedom liquid handling system with robotics arms. The vials were dried in genevac and were weighed to determine the final yield. A mother plate was prepared with the samples at 50  $\mu$ M concentration in DMSO, for *in vitro* screening (Scheme 1). The yield of the compounds ranged from 75–98%. The compounds were thoroughly characterized by <sup>1</sup>H, <sup>13</sup>C and high resolution mass spectroscopy.

### Pharmacological studies

**In vitro screening.** Once the synthesis is complete, the compounds were screened against  $\alpha$ -L-fucosidase (bovine kidney origin) with swainsonine as the standard inhibitor. In general the  $\alpha$ -L-fucosidase inhibitory effects of the compounds were measured at a concentration of 0.1  $\mu$ M to 50  $\mu$ M (0.1 → 1  $\mu$ M for compound **4f**; 1 → 10  $\mu$ M for compound **6a** and 10 → 50  $\mu$ M for the rest). To measure the potency of the compounds, the percentage inhibition observed, were plotted against the

concentrations using non-linear regression approach (sigmoid curves) (data not shown) from which their IC<sub>50</sub> values was computed (Table 3). Representatively 100  $\mu$ L of *p*-nitrophenol- $\alpha$ -L-fucoside substrate (2 mM, PNP-Fuc dissolved in 2 mM sodium citrate buffer at a pH of 4.2) and different concentrations (10–50  $\mu$ M) of the test compounds were taken in 96-well plates. Then the final volume of the reaction mixture was made up to 200  $\mu$ L with 2 mM sodium citrate buffer (pH 4.2). The hydrolytic reaction was commenced by the addition of  $\alpha$ -L-fucosidase enzyme (0.5 IU mL<sup>-1</sup>) (obtained from Sigma Aldrich, Bangalore) and the plates were incubated at 37 °C for 15 min. The reaction was terminated by the addition of 50  $\mu$ L of 2 N Na<sub>2</sub>CO<sub>3</sub> solution. The preliminary results indicated that compounds **4d–f** exhibited decent  $\alpha$ -L-fucosidase inhibition with IC<sub>50</sub> of ~0.7–3  $\mu$ M. The results are summarized in Table 2. To our utmost gratification compounds **4d–f** rendered inactive against healthy COS 1 cells, thereby indicating them to be nontoxic (refer ESI†).

### Structure activity relationship

$\alpha$ -L-Fucosidase inhibitory activity results obtained for our compounds revealed that the central moiety A and the aromatic or heteroaromatic appendage B influenced the primary



structure activity relationship within the library (Fig. 4). The methylene spacer between segment A and B apparently induce no influence in the activity of the molecule. From the inhibition results in Table 2, it is quite clear that: (a) the molecules with furopyridinedione in segment A *i.e.* **4a–4f** (other than **4c**), are significantly more active than their hydantoin and thiohydantoin counterparts; (b) the substituted thiophene derivatives (in segment B) such as **4d–4f** demonstrated substantially improved activity over their other aromatics and heteroaromatic analogs (**4a–4c**). Compound **4e** demonstrated the highest inhibitory effect against  $\alpha$ -L-fucosidase with  $IC_{50}$  concentration of  $0.68 \mu\text{M}$ . This is far better than the reference standard inhibitor, swainsonine (27.5 for  $\alpha$ -L-fucosidase) (Table 3).

Interestingly similar trend involving substituted thiophene was also observed with the thiohydantoin compounds, where **5c–5e** exhibited better inhibitory potency over **5a, b** and **f**.

Among the hydantoin analogs, **6a–6f** (Table 3) there was no substantial inhibitory activity. Only *p*-nitrophenyl derivative **6a**, was most active ( $IC_{50}$  of  $6.4 \mu\text{M}$ ). However the toxic legacy of nitro functionalities in drug discovery made it less promising. The fact that the hydantoin analogs did not possess the thiophene moiety in segment B, could be a reason for their inactivity.

Thorough analysis of the structure activity relationship further emphasized that the pyridone moiety and the substituted thiophene component complement each other in strengthening the binding with the enzyme. Interestingly the thiophene analogs of thiohydantoin scaffold exhibited better potency over the other compounds, though their overall activity was  $\sim 20$  times lesser than the thiophene analogs of pyridone scaffold. This further emphasized the importance of substituted thiophene and the pyridone scaffold in the SAR of our library.

### Reaction kinetics study

Inhibitory kinetic assay of the most potent compound **4e** was performed to identify the mode of inhibition of the most potent compound **4e** against  $\alpha$ -L-fucosidase. These inhibition kinetic studies were determined by graphical means applying primary (Lineweaver–Burk) and secondary plots. Fig. 5 illustrates the  $\alpha$ -L-fucosidase inhibition kinetic plots for compound **4e** (also please




Fig. 4 Structure activity relationship studies of the library of molecules against  $\alpha$ -L-fucosidase (bovine kidney origin).

refer ESI†). In Fig. 5 it was observed that all the data lines on the Lineweaver–Burk plots of **4e** intersected in the second quadrant indicating a mixed type of inhibition. The inhibition mechanism involves the binding of these inhibitors either to  $\alpha$ -L-fucosidase alone or the glycosidases + substrate complex. Hence, this sort of inhibition subsidizes two inhibition constants *viz.*  $K_1$  and  $K_2$ . The constants were determined from the slope of  $2^\circ$  plots and  $Y$  intercepts from LB-plot against the concentration of each inhibitor (data not shown in this paper). For compound **4e**, the  $K_1$  and  $K_2$  constants against  $\alpha$ -L-fucosidase were observed as  $0.63 \mu\text{M}$  and  $0.81 \mu\text{M}$ . The smaller dissociation constants demonstrate stronger inhibition of enzyme. Such mixed inhibition indicates the presence of an allosteric binding site in the enzyme where **4e** may bind to, instead of the primary binding site. One of the ways to confirm this is co-crystallizing **4e** with the enzyme followed by single crystal X-ray analysis. This is presently ongoing in our lab.

### Investigating anti-breast cancer properties of $\alpha$ -L-fucosidase inhibitors

The evolution of glycobiology in last thirty years revealed the role of carbohydrates in many human cancers. Very recently Listinsky *et al.* reported that fucose is responsible in various activities in breast cancer cells such as haematogenesis, metastasis, tumor invasion and epithelial cell migration.<sup>16</sup> Fucose has also been found in few breast cancer biomarkers namely E-selectin.<sup>17</sup> Such reports contained illustrative examples, *in vitro* study against breast cancer cells and clinical data from human screenings as evidence to support the hypothesis.

These reports prompted us to investigate the anti-breast cancer properties of our  $\alpha$ -L-fucosidase inhibitors. Accordingly we subjected the most potent inhibitors **4a–f**, to *in vitro* cytotoxicity assay against MCF 7 breast cancer cells. To our utmost gratification, among the six compounds screened, the heteroaryl substituted analogs **4a**, **4b**, **4e** and **4f** exhibited 50–85%




Fig. 5 Double-reciprocal (Lineweaver–Burk) plots of  $\alpha$ -L-fucosidase (bovine kidney) inhibition kinetics exhibited by compound **4e**;  $\alpha$ -L-fucosidase ( $0.5 \text{ IU mL}^{-1}$ ) was exposed to compound **4e** at  $37^\circ\text{C}$  for 10 min, followed by varying concentrations of *p*-nitrophenyl  $\alpha$ -L-fucoside (PNP-Fuc).



Table 4 Anti-breast cancer activity of selected  $\alpha$ -fucosidase inhibitors

| Entry | Compound number | MCF7 (MTT, 48 h) <sup>a</sup> |   |
|-------|-----------------|-------------------------------|---|
|       |                 | %ge inhibition                | EC <sub>50</sub> <sup>bc</sup> ( $\mu$ M) |
| 1     | Etoposide       | 84.30                         | —   |
| 2     | <b>4a</b>       | 49.50                         | —   |
| 3     | <b>4b</b>       | 60.39                         | —   |
| 4     | <b>4c</b>       | —                             | —   |
| 5     | <b>4d</b>       | —                             | —   |
| 6     | <b>4e</b>       | 62.02                         | —   |
| 7     | <b>4f</b>       | 84.92                         | 2.33                                      |

<sup>a</sup> All data is the mean of one experiment conducted in triplicates. <sup>b</sup> EC<sub>50</sub> of **4f** is the mean  $\pm$  SD of three experiments. <sup>c</sup> Unless otherwise indicated, the differences were considered to be statistically significant at  $P < 0.05$ . The analyses were performed using GraphPad Prism Software version 5.02 (GraphPad Inc., La Jolla, CA, USA).

inhibition of the proliferation of MCF 7 (Table 4, entry 2, 3, 6 and 7). Interestingly the most active  $\alpha$ -L-fucosidase inhibitor **4e** was only second best in deterring the proliferation of MCF 7 cells [62.02%] (Table 4, entry 5) to compound **4f**, which exhibits  $\sim$ 85% inhibition (at par with the reference drug etoposide). The half maximal inhibitory concentration (IC<sub>50</sub>) of **4f** is 2.3  $\mu$ M.

## Conclusion

Herein we have described discovery of a small heterocycles **4e** and **4f**, based on furopyridinedione that inhibits  $\alpha$ -L-fucosidase (bovine kidney origin) cells with low micromolar IC<sub>50</sub>. The original library comprising of the 6-methylfuro[3,4-c]pyridine-3, thiohydantoin and hydantoin molecules was designed by intuitive scaffold hopping and bioisosteric modification of known fucosidase and fucosyltransferase inhibitors. Molecular docking exercise among these molecules along with the enzymes rationalized the design. A small library of compounds containing all the three chemotypes was synthesized. They were then screened against  $\alpha$ -L-fucosidase (bovine kidney origin) with swainsonine as the reference standard. Furopyridinedione compound **4e**, with IC<sub>50</sub>  $\sim$  0.7  $\mu$ M emerged as the most active compound with potency nearly 40 fold more than the standard inhibitor. Reaction kinetics study indicated it to be a mixed inhibitor. Screening of **4e** against healthy mammalian COS cells indicated no cytotoxic effect. Correlation between fucose and breast cancer prompted further screening that resulted in **4a**, **b**, **e** and **f** exhibiting substantial inhibition of proliferation of MCF 7 breast cancer cells. All these results indicate that 6-methylfuro[3,4-c]pyridine-3,4(1H,5H)-dione molecules can be considered as promising lead against  $\alpha$ -L-fucosidase which in turn can be utilized to develop candidate for breast cancer.

## Methods

### Experimental

**Generation of 3D structures of candidate compounds.** The minimized 3D structures of the candidate compounds were generated using Schrodinger's LigPrep program where the SMILES strings of individual compounds were used as input.<sup>17</sup> LigPrep includes tautomeric, stereo-chemical, and ionization

variations, as well as energy minimization and flexible filters to generate fully customized ligand libraries optimized for further computational analyses.

### Homology modeling

Homology modeling of *Bos taurus*  $\alpha$ -L-fucosidase and subsequent loop modelling were performed using the MODELLER 9.11 package. Final models were subjected to energy minimization cycles in the GROMACS online energy minimization server and/or Schrodinger's restrained minimization program.<sup>18,19</sup> Validation of the final models (Fig. S1†) was done using the PROCHECK and Verify\_3D structure validation tools.<sup>20,21</sup> Root mean square deviations (RMSD) between the models and template structures were calculated using the CHIMERA structure visualization software.<sup>15</sup>

### Identification of inhibitor binding domain of $\alpha$ -L-fucosidase

The N- and C-terminal domains of  $\alpha$ -L-fucosidase are formed of  $\alpha$  +  $\beta$  secondary structure and all beta secondary structure, respectively. Known inhibitors bind to the N-terminal ( $\alpha/\beta$ ) domain (residues 1-357) of  $\alpha$ -L-fucosidase.

In order to ascertain the inhibitor binding domain of  $\alpha$ -L-fucosidase, a blind docking approach using PatchDock was employed for docking the dihydrofuro[3,4-c]pyridinone derivative (compound **4b**) to full-length bacterial (*Thermotoga maritima*)  $\alpha$ -L-fucosidase (PDB ID: 2ZX5).<sup>22</sup> Clustering analysis of the resultant solutions revealed that maximum number of solutions prefers binding of compound **4b** at the N terminal domain of 2ZX5 (Fig. S2 in ESI†).

A second blind docking of compound **4b** with only the N-terminal domain of 2ZX5 was performed to determine the binding pocket within the N-terminal binding domain. Clustering analysis revealed maximum number of solutions prefer binding of **4b** to that pocket of N-terminal 2ZX5, which is known to bind other conventional inhibitor compounds. Thus, blind docking experiments provide confidence to the assumption that **4b** and perhaps other similar derivatives may bind to the known inhibitor binding pocket located at N-terminus of  $\alpha$ -L-fucosidase.

### Molecular docking of candidate compounds to inhibitor binding pocket of $\alpha$ -L-fucosidase

The candidate compounds were docked to the known inhibitor binding pocket of N-terminal 2ZX5 using molecular docking software, *viz.*, FlexX.<sup>14</sup>

FlexX was used to predict the geometry of protein-ligand complex using a hybrid approach for placing ligand fragments in the active site. This hybrid approach combines the best of classic triangle matching and single interaction scan. A more negative value of FlexX score indicates better fit of ligand in the protein active site.

### In vitro inhibition screening assays of $\alpha$ -L-fucosidase

The effectiveness of the compounds on inhibition of  $\alpha$ -L-fucosidase (bovine kidney origin) was assessed in 96-well plates using



the respective substrate and buffering system according to the procedure reported by Ferreres *et al.*<sup>23</sup> Prior to assays, all the test compounds were dissolved in dimethylsulfoxide (DMSO) and eventually diluted to attain the desired concentration. The absorbance was measured spectrophotometrically at 400 nm (Epoch reader; version 2.00.18). The decrease in absorbance ( $\Delta A$ ) was compared with that of control (buffer instead of test compound) to compute the inhibitory profile of enzyme. The data used for the determination of  $IC_{50}$  concentrations were fitted by non-linear regression fitting and the variance analysis was carried out by using MINITAB 15 software (trial version). The concentration of inhibition required for 50% of  $\alpha$ -glucosidase activity under the assay conditions was defined as the  $IC_{50}$  value. The half maximal inhibitory ( $IC_{50}$ ) concentrations were determined from two independent assays, performed in duplicate.

$$\text{Inhibition (\%)} = (\Delta A_{\text{control}} - \Delta A_{\text{sample}})/\Delta A_{\text{control}} \times 100\%.$$

One unit (IU) is defined as the amount of enzyme ( $\alpha$ -glucosidase/ $\alpha$ -mannosidase/ $\alpha$ -L-fucosidase) which produces 1  $\mu\text{mol}$  of PNP (*p*-nitro phenol) per min at 37 °C under the respective reaction conditions described below.

For AFI, 100  $\mu\text{L}$  of *p*-nitrophenol- $\alpha$ -L-fucoside substrate (2 mM, PNP-Fuc dissolved in 2 mM sodium citrate buffer at a pH of 4.2) and different concentrations (10–50  $\mu\text{M}$ ) of the test compounds were taken in 96-well plates. Then the final volume of the reaction mixture was made up to 200  $\mu\text{L}$  with 2 mM sodium citrate buffer (pH 4.2). The hydrolytic reaction was commenced by the addition of  $\alpha$ -L-fucosidase enzyme (0.5 IU  $\text{mL}^{-1}$ ) (obtained from Sigma Aldrich, Bangalore) and the plates were incubated at 37 °C for 15 min. The reaction was terminated by the addition of 50  $\mu\text{L}$  of 2 N  $\text{Na}_2\text{CO}_3$  solution.

### Inhibition-kinetics

The kinetic mode of inhibition of the highest active compounds against three  $\alpha$ -L-fucosidase was determined as said above by preparing a series of test solutions in which the concentration of the respective substrate was varied in the presence of different concentrations of the inhibitors (10–50  $\mu\text{M}$ ). The mode of inhibition (*i.e.* competitive, non-competitive, uncompetitive or mixed-type) of the screened compounds was determined on the basis of the inhibitory effects on  $K_m$  (dissociation constant) and  $V_{\text{max}}$  (maximum reaction velocity) of the enzyme.<sup>24</sup> These studies were computed using the primary (Lineweaver–Burk plot) plots, which are the double reciprocal plots of enzyme reaction velocities ( $1/V$ ) *versus* substrate concentrations ( $1/[S]$ ). Analysis of the same data by secondary plots of slope *versus* [inhibitor] and  $Y$ -intercept *versus* [inhibitor] were also performed. The Lineweaver–Burk (LB) equation follows as:

$$\frac{1}{V} = \frac{1}{V_{\text{max}}} + \frac{K_m}{V_{\text{max}}} \times \frac{1}{[S]}$$

**Cell culture conditions.** MCF7 cells were maintained as monolayer in 25  $\text{cm}^2$  culture flasks (T-25) at 37 °C in DMEM medium (GIBCO, St. Louis, USA) supplemented with high glucose, L-glutamine, pyridoxine hydrochloride, 110 mg  $\text{L}^{-1}$

sodium pyruvate, 3.7 g  $\text{L}^{-1}$   $\text{NaHCO}_3$  and antibiotics (penicillin-10 000 units per mL, streptomycin-10 000  $\mu\text{g mL}^{-1}$ , Gibco USA). Growth medium (pH 7.4) was prepared by adding 5% heat inactivated FBS (Fetal Bovine Serum, Gibco, USA) and stored at 4 °C. The medium was changed 10–18 h prior to experiment, and cells were confluent at the time of experimentation. Cells were dislodged from flasks by gentle trypsinization containing 0.25% trypsin. MCF7 cells were regularly sub-cultured thrice a week in a seeding density of 40 000–50 000 cells per  $\text{cm}^2$  area.

**Cell viability assay (MTT assay).** The MTT colorimetric viability assay was performed to evaluate the anticancer effect of compounds. 30 000 cells/100  $\mu\text{L}$  of media were seeded per well and allowed to stretch and adhere overnight at 37 °C. Following day media was removed and 100  $\mu\text{L}$  fresh media was added to the grown cells. Adhered cells were then treated with the compounds **4a–f** dissolved in DMSO in triplicates at a standard concentration of 50  $\mu\text{M}$  for 48 hours. Cytotoxic effect was evaluated using ability of live cells to cleave MTT ((3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide)) (Sigma-Aldrich, St. Louis, MO, USA), into formazan crystals. Post 48 hours of treatment, 10  $\mu\text{L}$  of MTT (5 mg  $\text{mL}^{-1}$  in PBS) was added to the cells and incubated for 4 hours in dark at 37 °C. The violet colored crystals formed were then dissolved in 100  $\mu\text{L}$  DMSO solvent (dimethyl sulfoxide, Sigma-Aldrich, St. Louis, MO, USA). The colorimetric assay was read measured by a MultiMode Plate Reader (Bio-Rad) at 595 nm. Percentage of inhibition of drug was calculated by following formula:

$$\text{Percentage of inhibition} = (\text{Average of control O.D}_{595} - \text{average of treated O.D}_{595})/\text{control O.D}_{595} \times 100.$$

### Chemistry

All reactions were carried out in flame-dried pre-tared vials magnetic stirring. Unless otherwise noted, all experiments were performed under argon atmosphere. All reagents were purchased from Sigma Aldrich, Acros or Alfa Aesar. Solvents were treated with 4 Å molecular sieves or sodium and distilled prior to use.  $^1\text{H}$  NMR and  $^{13}\text{C}$  NMR spectra were recorded with tetramethylsilane (TMS) as internal standard at ambient temperature unless otherwise indicated on a Varian 300/400 and JEOL JNM-ECX500 MHz at 500 MHz for  $^1\text{H}$  NMR and 100 MHz for  $^{13}\text{C}$  NMR. Chemical shifts are reported in parts per million (ppm) and coupling constants are reported as Hertz (Hz). Splitting patterns are designated as singlet (s), broad singlet (bs), doublet (d), triplet (t). Splitting patterns that could not be interpreted or easily visualized are designated as multiple (m). The Mass Spectrometry analysis was done on the 6540 UHD Accurate-Mass Q-TOF LC/MS system (Agilent Technologies) equipped with Agilent 1290 LC system obtained by the Dept. of Chemistry, School of Natural Sciences, Shiv Nadar University, Uttar Pradesh 201314, India.

### Acknowledgements

We thank Shiv Nadar University, Department of Biotechnology (Breast Cancer-Pilot Grant) and CSIR-Indian Institute of



Chemical Biology for the financial support. SC acknowledges CSIR network project (BSC0121) and ST acknowledges DBT for funding. SG is supported by UGC fellowship grant.

## Notes and References

- 1 (a) P. E. Goss, M. A. Baker, J. P. Carver and J. W. Dennis, *Clin. Cancer Res.*, 1995, **1**, 935–944; (b) A. Herscovics, *Biochim. Biophys. Acta*, 1999, **1473**, 96–107; (c) N. Asano, *Glycobiology*, 2003, **13**, 93R–104R.
- 2 B. Winchester, *Glycobiology*, 2005, **15**, 1R–15R.
- 3 J. Van den Brink and R. P. de Vries, *Appl. Microbiol. Biotechnol.*, 2011, **91**, 1477–1492.
- 4 M. Günl, L. Neumetzler, F. Kraemer, A. de Souza, A. Schultink, M. Pena, W. S. York and M. Pauly, *Plant Cell*, 2011, **23**, 4025–4040.
- 5 T. K. Tolle, D. Glebe, M. Linder, D. Linder, S. Schmitt, R. Geyer and W. H. Gerlich, *J. Virol.*, 1998, **72**, 9978–9985.
- 6 T. W. Liu, C. W. Ho, H. H. Huang, S. M. Chang, S. D. Popat, Y. T. Wang, M. S. Wu, Y. J. Chen and C. H. Lin, *Proc. Natl. Acad. Sci. U. S. A.*, 2009, **106**, 14581–14586.
- 7 J. C. Michalski and A. Klein, *Biochim. Biophys. Acta, Mol. Basis Dis.*, 1999, **1455**, 69–84.
- 8 D. G. Hildebrand, S. Lehle, A. Borst, S. Haferkamp, F. Essmann and K. Schulze-Osthoff, *Cell Cycle*, 2013, **12**, 1922–1927.
- 9 J. Intra, *et al.*, *Gene*, 2007, **392**, 34–46.
- 10 (a) L. V. Hooper, *et al.*, *Proc. Natl. Acad. Sci. U. S. A.*, 1999, **96**, 9833–9838; (b) Z. Tu, Y.-N. Lin and C.-H. Lin, *Chem. Soc. Rev.*, 2013, **42**, 4459–4475; (c) C.-F. Chang, C.-W. Ho, C.-Y. Wu, T.-A. Chao, C.-H. Wong and C.-H. Lin, *Chem. Biol.*, 2004, **11**, 1301–1306; (d) E. Shitara, Y. Nishimura, F. Kojima and T. Takeuchi, *Bioorg. Med. Chem.*, 2000, **8**, 343–352; (e) O. Boss, E. Leroy, A. Blaser and J.-L. Reymond, *Org. Lett.*, 2000, **2**, 151–154.
- 11 G. A. Patani and E. J. LaVoie, *Chem. Rev.*, 1996, **96**, 3147–3176.
- 12 C. Ballatore, D. M. Huryn and A. B. Smith, *ChemMedChem*, 2011, **8**, 385–395.
- 13 E. Isabel, *et al.*, *Bioorg. Med. Chem. Lett.*, 2011, **21**, 920–923.
- 14 B. Kramer, M. Rarey and T. Lengauer, *Proteins: Struct., Funct., Genet.*, 1999, **37**, 228–241.
- 15 E. F. Pettersen, T. D. Goddard, C. C. Huang, G. S. Couch, D. M. Greenblatt, E. C. Meng and T. E. Ferrin, *J. Comput. Chem.*, 2004, **25**, 1605–1612.
- 16 J. J. Listinsky, G. P. Siegal and C. M. Listinsky, *Am. J. Transl. Res.*, 2011, **3**, 292–322.
- 17 *Schrödinger Release 2013-3: LigPrep*, version 2.8, Schrödinger, LLC, New York, NY, 2013.
- 18 E. Lindahl, C. Azuara, P. Koehl and M. Delarue, *Nucleic Acids Res.*, 2006, **34**, W52–W56.
- 19 *Schrödinger Release 2013-3: Maestro*, version 9.6, Schrödinger, LLC, New York, NY, 2013.
- 20 R. A. Laskowski, M. W. MacArthur, D. S. Moss and J. M. Thornton, *J. Appl. Crystallogr.*, 1993, **26**, 283–291.
- 21 D. Eisenberg, R. Luthy and J. U. Bowie, *Methods Enzymol.*, 1997, **277**, 396–404.
- 22 D. Schneidman-Duhovny, Y. Inbar, R. Nussinov and H. J. Wolfson, *Nucleic Acids Res.*, 2005, **33**, W363–W367.
- 23 F. Ferreres, A. Gil-Izquierdo, J. Vinholes, S. T. Silva, P. Valentao and P. B. Andrade, *Food Chem.*, 2012, **134**, 894–904.
- 24 B. T. Burlingham and T. S. Widlanski, *J. Chem. Educ.*, 2003, **80**, 214–218.